Tuesday, January 24th, 2017 Delcath Systems, Inc. (NASDAQ: DCTH) traded from a low of .308 to a high of .49 on over 13 million shares, for a respectable possible gain of 59%. Today, Wednesday the 25th of January DCTH consolidated, giving back some of those gains trading as low as .3624, down 14% from the prior days close finishing the session at .41.
With the volatility we have witnessed in the last couple trading sessions from DCTH we are definitely going to want to continue to keep apprised of the situation. Stocks coming off their 52-week lows like DCTH have potential to see some significant gains like we witnessed Tuesday once the price per share stabilizes. From this point forward if DCTH can maintain higher lows, StreetRegister.com will continue to keep track of its progress. To find out about more companies that are poised for prolific gains add your current email address in the sign up box below! Stay up to speed with DCTH’s story as it unfolds by subscribing at the bottom of the page.
Jan. 23, 2017 /PRNewswire/ — Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath will be a featured presenter at the NobleCon13 – Noble Capital Markets’ Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on Tuesday, January 31, 2017 at 10:30 am Eastern Standard Time.
A high-definition, video webcast of Delcath’s presentation will be available at http://noble.mediasite.com/mediasite/Play/b9ba93421f9245eb8a86b42ab119a0161d. A Microsoft SilverLight viewer (a free download from the presentation link) is required to participate. The webcast and presentation will be archived on the Company’s website at www.delcath.com and on the Noble websites, www.noblecapitalmarkets.com, or www.nobleconference.com, for 90 days following the event. Management will also be available for one-on-one meetings on January 30 and 31, 2017.
About Noble Capital Markets, Inc.
Noble Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York and Boston. In addition to NobleCon – the annual multi-sector investor conference and the Media, Finance & Investor Conference, produced in partnership with the National Association of Broadcasters (NAB) and held each spring in Las Vegas, throughout the year Noble hosts numerous “non-deal” corporate road shows across the United States and Canada. Members: FINRA, SIPC, MSRB. www.noblecapitalmarkets.com
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and a global Phase 2 clinical trial in Europe and the U.S. to investigate the Melphalan/HDS system for the treatment of primary liver cancer (HCC) and intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
Currently bouncing off its 52-week lows DCTH shares have offered gains more than 50% in market value in a single session. StreetRegister.com is always uncovering undervalued smallcap opportunities like DCTH that are bouncing off 52-week lows. Be sure to be subscribed to the Streetregister.com newsletter to receive additional information on DCTH and other stocks that are poised for fast profits. Stay up to date as the backdrop of DCTH develops by subscribing to our newsletter, just enter your email in the subscribe box below! Sign up Today!